Crohn's disease Archives -

AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

https://pharmaphorum.com/news/abbvies-skyrizi-beats-il-23-rivals-to-crohns-disease-approval/

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Phil Taylor AbbVie, Crohn's disease, inflammatory bowel disease, Rinvoq 0 Comment

AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

https://pharmaphorum.com/news/third-positive-trial-sets-up-filings-for-abbvies-rinvoq-in-crohns/

Market Access/ News/ News

Takeda bags Japanese approval for Crohn’s cell therapy Alofisel

Phil Taylor Alofisel, cell therapy, Crohn's disease, Japan, regulatory approval, Takeda 0 Comment

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn’s disease, becoming

Takeda bags Japanese approval for Crohn’s cell therapy Alofisel

https://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/

News/ News/ R&D

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

Phil Taylor Crohn's disease, dermatology, Eli Lilly, gastrointestinal, Immunology and inflammation, mirikizumab, psoriasis, ulcerative colitis 0 Comment

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

https://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/

News

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

Richard Staines AbbVie, Allergan, AstraZeneca, brazikumab, Crohn's disease, M&A, ulcerative colitis 0 Comment

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

https://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/

News

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

Richard Staines Allergan, AstraZeneca, Crohn's disease, inflammatory diseases, ulcerative colitis 0 Comment

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

https://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/

Market Access/ News/ News

Allergan says it will shed two drugs as AbbVie takeover looms

Phil Taylor AbbVie, Allergan, brazikumab, Crohn's disease, inflammatory bowel disease, M&A, ulcerative colitis 0 Comment

Allergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead

Allergan says it will shed two drugs as AbbVie takeover looms

https://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/

News/ News/ R&D

Abivax sets its course on colitis and Crohn’s

Piotr Wnuk Abivax, Crohn's disease, ulcerative colitis 0 Comment

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464

Abivax sets its course on colitis and Crohn’s

https://pharmaphorum.com/news/abivax-scolitis-crohns/

Market Access/ News/ News

Takeda finalises buyout of TiGenix

Joy Persaud CHMP, Crohn's disease, Takeda, TiGenix 0 Comment

Japanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology

Takeda finalises buyout of TiGenix

https://pharmaphorum.com/news/japanese-takeda-finalises-tigenix-boyout/

Trending

Crohn’s disease

Login